Ironwood Pharmaceuticals Stock Z Score

IRWD Stock  USD 8.71  0.09  1.04%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Valuation analysis.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
  
At present, Ironwood Pharmaceuticals' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 3.44, whereas Capital Lease Obligations is forecasted to decline to about 9.9 M. At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M.

Ironwood Z Score Analysis

Ironwood Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 2023 2024 (projected)
Interest Expense31.2M7.6M21.6M19.9M
Depreciation And Amortization682K9.5M1.6M1.5M

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

Current Ironwood Pharmaceuticals Z Score

    
  -1.61  
Most of Ironwood Pharmaceuticals' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ironwood Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Ironwood Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Ironwood Pharmaceuticals is extremely important. It helps to project a fair market value of Ironwood Stock properly, considering its historical fundamentals such as Z Score. Since Ironwood Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ironwood Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ironwood Pharmaceuticals' interrelated accounts and indicators.
-0.010.70.050.16-0.16-0.18-0.20.930.60.60.210.660.490.950.20.58-0.280.440.620.650.060.5-0.370.280.650.15
-0.01-0.46-0.28-0.280.68-0.43-0.43-0.250.220.50.550.080.34-0.10.750.09-0.490.670.250.25-0.290.26-0.5-0.14-0.51-0.59
0.7-0.46-0.090.41-0.780.44-0.180.820.01-0.04-0.30.22-0.20.75-0.350.250.270.150.00.05-0.07-0.02-0.050.40.910.43
0.05-0.28-0.09-0.190.15-0.010.660.060.11-0.19-0.26-0.010.29-0.12-0.35-0.030.06-0.550.11-0.050.980.560.76-0.01-0.120.05
0.16-0.280.41-0.19-0.480.36-0.460.28-0.25-0.11-0.39-0.11-0.250.22-0.07-0.140.190.07-0.27-0.15-0.21-0.27-0.050.530.40.37
-0.160.68-0.780.15-0.48-0.790.16-0.430.450.460.680.290.6-0.290.650.28-0.390.160.480.430.150.45-0.15-0.29-0.79-0.52
-0.18-0.430.44-0.010.36-0.79-0.130.07-0.8-0.74-0.81-0.77-0.74-0.12-0.51-0.710.42-0.08-0.83-0.83-0.05-0.460.370.340.390.19
-0.2-0.43-0.180.66-0.460.16-0.13-0.150.01-0.350.030.060.06-0.3-0.290.150.4-0.640.01-0.070.690.220.59-0.41-0.290.01
0.93-0.250.820.060.28-0.430.07-0.150.40.39-0.020.490.30.88-0.020.4-0.130.270.40.450.060.33-0.240.20.790.33
0.60.220.010.11-0.250.45-0.80.010.40.820.510.90.890.530.310.79-0.530.150.990.950.140.61-0.39-0.180.110.17
0.60.5-0.04-0.19-0.110.46-0.74-0.350.390.820.670.740.770.560.580.58-0.770.50.850.9-0.20.53-0.71-0.060.09-0.14
0.210.55-0.3-0.26-0.390.68-0.810.03-0.020.510.670.60.440.180.670.59-0.310.370.560.67-0.240.28-0.54-0.28-0.34-0.49
0.660.080.22-0.01-0.110.29-0.770.060.490.90.740.60.680.630.240.95-0.240.110.910.940.040.47-0.39-0.130.240.21
0.490.34-0.20.29-0.250.6-0.740.060.30.890.770.440.680.340.470.53-0.640.20.880.830.280.69-0.3-0.2-0.130.07
0.95-0.10.75-0.120.22-0.29-0.12-0.30.880.530.560.180.630.340.10.55-0.250.420.560.6-0.090.25-0.450.320.750.16
0.20.75-0.35-0.35-0.070.65-0.51-0.29-0.020.310.580.670.240.470.10.21-0.40.760.330.43-0.320.21-0.66-0.06-0.47-0.51
0.580.090.25-0.03-0.140.28-0.710.150.40.790.580.590.950.530.550.21-0.010.10.80.820.050.42-0.31-0.110.170.16
-0.28-0.490.270.060.19-0.390.420.4-0.13-0.53-0.77-0.31-0.24-0.64-0.25-0.4-0.01-0.39-0.54-0.520.12-0.40.530.090.020.22
0.440.670.15-0.550.070.16-0.08-0.640.270.150.50.370.110.20.420.760.1-0.390.170.26-0.560.09-0.760.270.05-0.38
0.620.250.00.11-0.270.48-0.830.010.40.990.850.560.910.880.560.330.8-0.540.170.960.140.62-0.41-0.160.10.08
0.650.250.05-0.05-0.150.43-0.83-0.070.450.950.90.670.940.830.60.430.82-0.520.260.96-0.020.53-0.53-0.140.130.1
0.06-0.29-0.070.98-0.210.15-0.050.690.060.14-0.2-0.240.040.28-0.09-0.320.050.12-0.560.14-0.020.510.74-0.05-0.140.05
0.50.26-0.020.56-0.270.45-0.460.220.330.610.530.280.470.690.250.210.42-0.40.090.620.530.510.060.07-0.02-0.11
-0.37-0.5-0.050.76-0.05-0.150.370.59-0.24-0.39-0.71-0.54-0.39-0.3-0.45-0.66-0.310.53-0.76-0.41-0.530.740.060.09-0.120.19
0.28-0.140.4-0.010.53-0.290.34-0.410.2-0.18-0.06-0.28-0.13-0.20.32-0.06-0.110.090.27-0.16-0.14-0.050.070.090.370.03
0.65-0.510.91-0.120.4-0.790.39-0.290.790.110.09-0.340.24-0.130.75-0.470.170.020.050.10.13-0.14-0.02-0.120.370.52
0.15-0.590.430.050.37-0.520.190.010.330.17-0.14-0.490.210.070.16-0.510.160.22-0.380.080.10.05-0.110.190.030.52
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

According to the company's disclosures, Ironwood Pharmaceuticals has a Z Score of -1.61. This is 123.85% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The z score for all United States stocks is 118.46% higher than that of the company.

Ironwood Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.
Ironwood Pharmaceuticals is currently under evaluation in z score category among related companies.

Ironwood Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Ironwood Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ironwood Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ironwood Pharmaceuticals' value.
Shares
Geode Capital Management, Llc2023-12-31
3.1 M
Jacobs Levy Equity Management, Inc.2023-09-30
2.4 M
Jupiter Asset Management Limited2023-12-31
2.3 M
Goldman Sachs Group Inc2023-12-31
2.2 M
Morgan Stanley - Brokerage Accounts2023-12-31
2.1 M
Nuveen Asset Management, Llc2023-12-31
1.8 M
Northern Trust Corp2023-12-31
1.6 M
Driehaus Capital Management Llc2023-12-31
1.6 M
Adage Capital Partners Gp Llc2023-12-31
1.5 M
Blackrock Inc2023-12-31
26 M
Sarissa Capital Management Lp2023-09-30
16.4 M

Ironwood Fundamentals

About Ironwood Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Check out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Valuation analysis.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Valuation
Check real value of public entities based on technical and fundamental data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.69)
Earnings Share
(6.45)
Revenue Per Share
2.848
Quarterly Revenue Growth
0.097
Return On Assets
0.1339
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.